Quality ID #180: Rheumatoid Arthritis (RA): Glucocorticoid Management  
– National Quality Strategy Domain: Effective Clinical Care  
– Meaningful Measure Area: Management of Chronic Conditions

2020 COLLECTION TYPE:  
MIPS CLINICAL QUALITY MEASURES (CQMS)

MEASURE TYPE:  
Process

DESCRIPTION:  
Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis (RA) who have been assessed for glucocorticoid use and, for those on prolonged doses of prednisone >5 mg daily (or equivalent) with improvement or no change in disease activity, documentation of glucocorticoid management plan within 12 months

INSTRUCTIONS:  
This measure is to be submitted a minimum of once per performance period for patients with a diagnosis of RA who are seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Submission Type:  
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR:  
Patients aged 18 years and older with a diagnosis of RA

Denominator Criteria (Eligible Cases):  
Patients aged ≥ 18 years on date of encounter  
AND  
Diagnosis for rheumatoid arthritis (RA) (ICD-10-CM): M05.00, M05.011, M05.012, M05.019, M05.021, M05.022, M05.029, M05.031, M05.032, M05.039, M05.041, M05.042, M05.049, M05.051, M05.052, M05.059, M05.061, M05.062, M05.069, M05.071, M05.072, M05.079, M05.09, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152, M05.159, M05.161, M05.162, M05.169, M05.171, M05.172, M05.179, M05.19, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.29, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.622, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649,
M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.771, M05.772, M05.779, M05.79, M05.80, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.869, M05.871, M05.872, M05.879, M05.89, M06.00, M06.011, M06.012, M06.019, M06.021, M06.022, M06.029, M06.031, M06.032, M06.039, M06.041, M06.042, M06.049, M06.051, M06.052, M06.059, M06.061, M06.062, M06.069, M06.071, M06.072, M06.079, M06.08, M06.09, M06.20, M06.211, M06.212, M06.219, M06.221, M06.222, M06.229, M06.231, M06.232, M06.239, M06.241, M06.242, M06.249, M06.251, M06.252, M06.259, M06.261, M06.262, M06.269, M06.271, M06.272, M06.279, M06.28, M06.29, M06.30, M06.311, M06.312, M06.319, M06.321, M06.322, M06.329, M06.331, M06.332, M06.341, M06.342, M06.349, M06.351, M06.352, M06.359, M06.361, M06.362, M06.369, M06.371, M06.372, M06.379, M06.38, M06.39, M06.40, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89, M06.89, M06.9

AND

Patient encounter during the performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, G0402

WITHOUT

Telehealth Modifier: GQ, GT, 95, POS 02

NUMERATOR:
Patients who have been assessed for glucocorticoid use and for those on prolonged doses of prednisone >5 mg daily (or equivalent) with improvement or no change in disease activity, documentation of a glucocorticoid management plan within 12 months

Definitions:
Prolonged Dose – Doses > 6 months in duration.
Prednisone Equivalents – Determine using the following:
1 mg of prednisone = 1 mg of prednisolone; 5 mg of cortisone; 4 mg of hydrocortisone; 0.8 mg of triamcinolone; 0.8 mg of methylprednisolone; 0.15 mg of dexamethasone; 0.15 mg of betamethasone.
Glucocorticoid Management Plan – Includes documentation of attempt to taper steroids OR documentation of a new prescription for a non-glucocorticoid disease-modifying anti-rheumatic drug (DMARD) OR increase in dose of non-glucocorticoid DMARD dose for persistent RA disease activity at current or reduced dose.

Numerator Options:
Performance Met:
Patient not receiving glucocorticoid therapy (4192F)

OR
Performance Met:
Patient receiving ≤5 mg daily prednisone (or equivalent), or RA activity is worsening, or glucocorticoid use is for less than 6 months (G2112)

OR
Performance Met:
Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity (G2113)

AND
Glucocorticoid Management Plan documented (0540F)

OR
Denominator Exception: Documentation of medical reason(s) for not documenting glucocorticoid management plan (i.e., glucocorticoid prescription is for a medical condition other than RA) (0540F with 1P)

AND

Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity (G2113)

OR

Performance Not Met: Glucocorticoid dose was not documented, reason not otherwise specified (4194F with 8P)

OR

Performance Not Met: Glucocorticoid management plan not documented, reason not otherwise specified (0540F with 8P)

AND

Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity (G2113)
RATIONALE:
Glucocorticoids are an important part of RA treatment as they inhibit inflammation and may control synovitis. However, long-term use of glucocorticoids, especially at high doses, should be avoided, due to the potential health complications. Monitoring length and dose of glucocorticoid treatment for patients with RA is integral to making other clinical decisions.

CLINICAL RECOMMENDATION STATEMENTS:
Low-dose oral glucocorticoids and local injections of glucocorticoids are highly effective for relieving symptoms in patients with active RA. The benefits of low-dose systemic glucocorticoids, however, should always be weighed against their adverse effects. The adverse effects of long-term oral glucocorticoids at low doses are protean and include osteoporosis, hypertension, weight gain, fluid retention, hyperglycemia, cataracts, and skin fragility, as well as the potential for premature atherosclerosis. These adverse effects should be considered and should be discussed in detail with the patient before glucocorticoid therapy is begun. For long term disease control, the glucocorticoid dosage should be kept to a minimum. For the majority of patients with RA, this means equal or less than 10 mg of prednisone per day. (ACR, 2002)

Grijalva, et al found nearly two-fold greater serious infection (OR1.78 1.47,2.15) at 5-10 mg of prednisone in RA as reported in JAMA 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692. Epub 2011 Nov 6. Because of the dangers to patients associated with being on 5 to 10 mg doses of prednisone, optimal treatment is to aim for a dosage less than or equal to 5 mg.

COPYRIGHT:
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or American College of Rheumatology (ACR). Neither the AMA, ACR, PCPI, nor its members shall be responsible for any use of the Measures.

The AMA’s, PCPI’s and National Committee for Quality Assurance’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. ACR is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of July 25, 2014.

ACR encourages use of the Measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2014 American Medical Association and American College of Rheumatology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ACR, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

2020 Clinical Quality Measure Flow for Quality ID #180: Rheumatoid Arthritis (RA): Glucocorticoid Management

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.

Data Completeness Met + Performance Met 4182F or equivalent (20 patients)

Data Completeness Met + Performance Met G2112 or equivalent (10 patients)

Data Completeness Met + Performance Met G2113 AND 0540F or equivalent (19 patients)

Data Completeness Met + Denominator Exception 0540F with SP AND G2113 or equivalent (10 patients)

Data Completeness Met + Performance Not Met 4194F with SP or equivalent (20 patients)

Data Completeness Met + Performance Not Met 0540F with SP AND G2113 or equivalent (6 patients)
**SAMPLE CALCULATIONS:**

Data Completeness:

\[
\text{Performance Met (a') + Performance Not Met (b') - 40 patients)} + \text{Denominator Exception (b' - 10 patients)} = \text{70 patients} = 87.50\%
\]

Eligible Population / Denominator (d = 80 patients) = 80 patients

Performance Rate:

\[
\text{Performance Met (a') - 40 patients) = 40 patients = 66.67\%}
\]

Data Completeness Numerator (70 patients) - Denominator Exception (b' - 10 patients) = 60 patients

*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process
2020 Clinical Quality Measure Flow Narrative for Quality ID #180:
Rheumatoid Arthritis (RA): Glucocorticoid Management

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.

1. Start with Denominator

2. Check Patient Age:
   a. If Patients Age is greater than or equal to 18 Years on Date of Encounter and equals No during the measurement period, do not include in Eligible Population. Stop Processing.
   b. If Patients Age is greater than or equal to 18 Years on Date of Encounter and equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of Rheumatoid Arthritis as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis of Rheumatoid Arthritis as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier.

5. Check Telehealth Modifier:
   a. If Telehealth Modifier equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Telehealth Modifier equals No, include in Eligible Population.

6. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.

7. Start Numerator

8. Check Patient Not Receiving Glucocorticoid Therapy:
   a. If Patient Not Receiving Glucocorticoid Therapy equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a’ equals 20 patients in the Sample Calculation.
c. If Patient Not Receiving Glucocorticoid Therapy equals No, proceed to check Patient Receiving Less Than or equal to 5 mg Daily Prednisone (or Equivalent), or RA Activity is Worsening, or Glucocorticoid Use is for Less Than 6 Months.

9. Check Patient Receiving Less Than or equal to 5 mg Daily Prednisone (or Equivalent), or RA Activity is Worsening, or Glucocorticoid Use is for Less Than 6 Months:
   a. If Patient Receiving Less Than or equal to 5 mg Daily Prednisone (or Equivalent), or RA Activity is Worsening, or Glucocorticoid Use is for Less Than 6 Months equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a² equals 10 patients in the Sample Calculation.
   c. If Patient Receiving Less Than or equal to 5 mg Daily Prednisone (or Equivalent), or RA Activity is Worsening, or Glucocorticoid Use is for Less Than 6 Months equals No, proceed to check Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity AND Glucocorticoid Management Plan Documented.

10. Check Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity AND Glucocorticoid Management Plan Documented:
    a. If Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity AND Glucocorticoid Management Plan Documented equals Yes, include in Data Completeness Met and Performance Met.
    b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a³ equals 10 patients in the Sample Calculation.
    c. If Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity AND Glucocorticoid Management Plan Documented equals No, proceed to check Documentation of Medical Reason(s) for Not Documenting Glucocorticoid Management Plan (i.e., Glucocorticoid Prescription is for a Medical Condition Other Than RA) AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity.

11. Check Documentation of Medical Reason(s) for Not Documenting Glucocorticoid Management Plan (i.e., Glucocorticoid Prescription is for a Medical Condition Other Than RA) AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity:
    a. If Documentation of Medical Reason(s) for Not Documenting Glucocorticoid Management Plan (i.e., Glucocorticoid Prescription is for a Medical Condition Other Than RA) AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity equals Yes, include in Data Completeness Met and Denominator Exception.
    b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 patients in the Sample Calculation.
c. If Documentation of Medical Reason(s) for Not Documenting Glucocorticoid Management Plan (i.e., Glucocorticoid Prescription is for a Medical Condition Other Than RA) AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months, and Improvement or No Change in Disease Activity equals No, proceed to check Glucocorticoid Dose Not Documented, Reason Not Otherwise Specified.

12. Check Glucocorticoid Dose Not Documented, Reason Not Otherwise Specified:

a. If Glucocorticoid Dose Not Documented, Reason Not Otherwise Specified equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter \( c^1 \) equals 20 patients in the Sample Calculation.

c. If Glucocorticoid Dose Not Documented, Reason Not Otherwise Specified equals No, proceed to check Glucocorticoid Management Plan Not Documented, Reason Not Otherwise Specified AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months and Improvement or No Change in Disease Activity.

13. Check Glucocorticoid Management Plan Not Documented, Reason Not Otherwise Specified AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months and Improvement or No Change in Disease Activity:

a. If Glucocorticoid Management Plan Not Documented, Reason Not Otherwise Specified AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months and Improvement or No Change in Disease Activity equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter \( c^2 \) equals 0 patients in the Sample Calculation.

c. If Glucocorticoid Management Plan Not Documented, Reason Not Otherwise Specified AND Patient Receiving Greater Than 5 mg Daily Prednisone (or Equivalent) for Longer Than 6 Months and Improvement or No Change in Disease Activity equals No, proceed to check Data Completeness Not Met.

14. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

---

**SAMPLE CALCULATION:**

\[
\text{Data Completeness} = \frac{\text{Performance Met} (a^1 + b^1 = 40 \text{ patients}) + \text{Denominator Exception} (b^2 = 10 \text{ patients}) + \text{Performance Not Met} (c^1 + c^2 = 20 \text{ patients})}{\text{Eligible Population} (d = 80 \text{ patients})} = 70 \text{ patients} = 87.50\% \\
\text{Performance Rate} = \frac{\text{Performance Met} (a^1 + b^1 = 40 \text{ patients})}{\text{Data Completeness Numerator} (70 \text{ patients})} = 56.67\% \\
\text{Data Completeness Numerator} (70 \text{ patients}) = 70 \text{ patients} - 10 \text{ patients} = 60 \text{ patients}
\]